Your browser does not support JavaScript! News Archive | Biofidelity

News

Press Releases


Biofidelity announced the publication of data that highlights how Aspyre® technology addresses the urgent need for rapid, accessible molecular diagnostics informing actionable genomic variants in cancer.


Biofidelity today announced the launch of Aspyre Clinical Test for Lung for liquid biopsy samples. Aspyre Clinical Test for Lung analyzes all guideline-recommended genes for non-small cell lung cancer (NSCLC) patients in both DNA and RNA from tissue and blood within two days, benefitting patients by enabling earlier treatment decisions.


Biofidelity, a leader in innovative genomic solutions, today announced the launch of Aspyre Lung Reagents (research use only) for liquid biopsy samples. Aspyre Lung identifies established non-small cell lung cancer (NSCLC) biomarkers in both DNA and RNA from tissue and blood.


View All

Media Coverage


Cancer molecular diagnostics company Biofidelity this week presented the results of three studies the American Association for Cancer Research (AACR) annual meeting showcasing the consistency, reproducibility, and superiority in certain sample types with Aspyre Lung.


Biofidelity’s successful $24 million financing round, which brings the total funding raised to $60m since being founded in 2019, will accelerate the growth of its game-changing Aspyre Lung genomic testing protocol.


Biofidelity, a genomic technology company with headquarters in the Research Triangle Park, has raised $24 million from investors in a new round of funding.


View All